Peptide PilotPeptide Pilot

mg ↔ units

Sermorelin mg to units converter

Set your Sermorelin vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

mg

0.200

units

8.00

mL

0.080

Concentration: 2.50 mg/mL (assumes a U-100 insulin syringe).

Sermorelin is a daily evening injection people use to bump up their own natural growth hormone production, usually for sleep quality, recovery, and skin and body-composition changes. It's a shortened version of the body's GHRH signal, so it nudges the pituitary instead of replacing GH from outside. Clinical studies in adults show modest but measurable IGF-1 increases over months of nightly use. This page covers reconstitution math and nightly logging cadence.

How the Sermorelin mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the Sermorelin concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 2.5 mg/mL Sermorelin solution, 0.2 mg comes out to 8 units, and 8 units comes out to 0.2 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 5 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for Sermorelin

Sermorelin is a synthetic peptide representing the first 29 amino acids of human growth hormone-releasing hormone (GHRH), making it the shortest functional GHRH analog in common use. Originally synthesized in the 1970s, it has one of the longest research histories of any peptide in its class. This 29-amino-acid structure preserves the full intrinsic activity of native GHRH, allowing it to bind effectively to its target receptor in the pituitary gland. Its identity is fundamentally tied to being the minimal active fragment of the endogenous hormone.

The extensive history of Sermorelin includes its formulation as an FDA-approved diagnostic agent and therapeutic for pediatric growth hormone deficiency under the brand name Geref. Although this product was later discontinued for commercial reasons unrelated to its safety profile, the data from its clinical use provides a substantial body of knowledge. The peptide's characteristically short biological half-life, estimated at around 10 to 20 minutes, is a defining trait that dictates the common single daily dosing schedule observed in research protocols.

To fully document the history of sermorelin, it is important to understand the context of its former commercial branding. For many years, sermorelin acetate was manufactured by Serono under the brand name Geref Diagnostic. The intended application for this product was as a diagnostic agent to assess the pituitary gland's capacity to secrete growth hormone. However, in November of 2008, the manufacturer officially discontinued the product, a decision that has since been the source of some confusion for independent researchers.

Sermorelin mechanism in plain English

Sermorelin functions by binding to and stimulating the growth hormone-releasing hormone receptor (GHRHR) located on somatotroph cells in the anterior pituitary. This action directly mimics the physiological role of endogenous GHRH. Activation of the GHRHR initiates a signaling cascade that results in the synthesis and subsequent release of the pituitary's own stored growth hormone (GH). Because Sermorelin is cleared from the body rapidly, the resulting GH release is a discrete pulse, a characteristic often described as 'pulse-preserving'. This mechanism is fundamentally different from direct GH administration, which creates sustained, non-pulsatile levels of the hormone.

The functional mechanism of sermorelin can also be viewed through the lens of circadian biology. As a GHRH analog, it stimulates pituitary somatotrophs to release growth hormone, but the timing of this stimulation in research protocols is often deliberate. The body’s most significant endogenous GH pulse occurs during the initial phase of slow-wave sleep early in the nightly sleep cycle. Research protocols often explore administration just before this period to study how the peptide interacts with the body's peak natural pituitary activity. This allows observers to document how sermorelin's mechanism integrates with a pre-existing physiological rhythm.

Tracking Sermorelin unit counts

For anyone studying Sermorelin, the most challenging variable to reconstruct from memory is the strict adherence to a bedtime dosing schedule over multi-week or multi-month periods. It is easy to forget whether a dose was administered or if the timing deviated from the pre-sleep window on any given night. Logging the exact time of each administration creates an indelible record of protocol consistency. This timeline becomes essential for any future effort to correlate observed effects with adherence, as inconsistencies in timing directly impact the interaction with the body's natural GH pulse.

Meticulous personal record-keeping can extend beyond logging just the dosage and time, especially when studying sleep-related variables. An individual can track a variety of subjective metrics to create a more complete dataset for future observation. Data points to log might include the time of administration, the time of sleep onset, the number of awakenings during the night, and a qualitative score for morning alertness or perceived restfulness. By consistently scheduling and recording these qualitative observations alongside the quantitative dose data, a person can later analyze the documented information for potential correlations.

Common Sermorelin conversion mistakes

  • Mistaking its short half-life for a lack of activity and consequently attempting to use multi-day dosing intervals.
  • Dosing in the morning, which works against the body's natural GH circadian rhythm and the peptide's designed function.
  • Assuming it operates identically to longer-acting GHRH analogs and failing to maintain a rigid nightly administration schedule.
  • Using a very low diluent volume, such as 0.5 mL, which makes the accurate measurement of a typical 200 mcg dose exceedingly difficult on a U-100 syringe.
  • Neglecting to document the precise time of evening administration, which makes it impossible to audit adherence to the pre-sleep protocol later.
  • Misattributing the 2008 discontinuation of the commercial product Geref Diagnostic to safety problems, when public records show it was for commercial reasons related to sales volume.
  • Failing to document the precise administration time relative to sleep, which makes it difficult to analyze any observations in the context of the body's natural circadian GH release.
  • Assuming that any administration time of day is equivalent, thereby ignoring the body of research that specifically studies nighttime administration to coincide with slow-wave sleep.

Frequently asked questions about Sermorelin mg ↔ units

Why is Sermorelin composed of only the first 29 amino acids of GHRH?
Sermorelin is structured as the N-terminal fragment of native Growth Hormone-Releasing Hormone because extensive research identified this segment as the biologically active region. These 29 amino acids are sufficient for binding to and stimulating the GHRH receptor with the same efficacy as the full 44-amino-acid hormone. The remaining C-terminal portion of the natural peptide is not required for this primary function.
What is meant by a 'pulse-preserving' stimulus in the context of Sermorelin?
This term describes how Sermorelin's rapid action and clearance imitate a natural GHRH signal from the brain. It causes a discrete, short-lived release of GH from the pituitary, after which the peptide is quickly eliminated from the system. This mechanism allows the body's own regulatory feedback loops and subsequent natural GH pulses to function without interference, in contrast to the sustained hormone levels produced by direct GH administration.
Why is Sermorelin's dosing schedule typically set for right before bed?
The human body's most significant natural surge of GH occurs during the early stages of deep sleep, shortly after nightfall. By scheduling a Sermorelin dose immediately before sleep, the peptide's peak action is timed to coincide with this powerful natural event. This strategy aims to amplify the body's own largest GH pulse instead of generating a separate pulse at a non-physiological time.
With a 5 mg vial and 2 mL of diluent, how many units is a 200 mcg dose?
When a 5 mg vial of powder is reconstituted with 2 mL of bacteriostatic water, the resulting solution has a concentration of 2,500 mcg per mL. To draw a 200 mcg dose, the calculated volume is 0.08 mL. On a U-100 insulin syringe, this volume corresponds exactly to the 8-unit mark.
Is the very short half-life of Sermorelin considered a disadvantage?
Its short half-life, estimated at 10 to 20 minutes, is a defining functional characteristic rather than an inherent flaw. This rapid clearance is precisely what enables Sermorelin to produce a brief, pulsatile stimulus that closely mimics the body's natural GHRH signaling pattern. Other analogs with longer half-lives produce a more sustained stimulation, which represents a fundamentally different mechanism of action and physiological effect.
Given its age, has research on Sermorelin been superseded by newer analogs?
While newer GHRH analogs with different properties now exist, Sermorelin's extensive history since the 1970s provides an exceptionally deep catalog of research data. Its former status as an FDA-approved drug means it has been rigorously studied for its specific pulsatile mechanism. It remains a valuable reference compound for understanding GHRH receptor pharmacology and the physiological response to short-acting stimuli.
Why is sermorelin administration often studied with a bedtime dosing schedule?
Research protocols often schedule sermorelin administration before sleep to align with the body's natural circadian rhythm. The largest and most predictable pulse of endogenous growth hormone (GH) occurs during the first period of slow-wave sleep, typically within the initial hours after sleep onset. Studies aiming to observe the effects of augmenting this natural pulse therefore time the administration accordingly. This allows researchers to document the peptide's interaction with the body’s existing hormonal architecture.
Was the sermorelin-based product Geref taken off the market for safety reasons?
No, the discontinuation of Geref Diagnostic by its manufacturer, EMD Serono, in 2008 was publicly stated to be for commercial reasons. The product was approved as a diagnostic agent, and low market demand made its continued production financially unviable for the company. The decision was not driven by safety or efficacy issues with sermorelin itself, a point that is critical for accurately documenting its history.
What is the structural relationship between sermorelin and the body's own GHRH?
Sermorelin is a synthetic peptide that represents a fragment of the native human Growth Hormone-Releasing Hormone (GHRH). Specifically, it is composed of the first 29 amino acids of the full 44-amino-acid GHRH molecule. Scientific studies identified this 1-29 segment as the biologically active portion of the hormone responsible for its function. Therefore, sermorelin is documented as a direct GHRH analog because it directly mimics the functional part of the endogenous hormone.

Related on Peptide Pilot

Save your Sermorelin vial in the app

Download on the App Store
Get the App